Skip to main content

“Grindeks” unveils new look

“Grindeks” unveils new lookJSC “Grindeks” announces an update to its corporate brand, including refreshed logo, custom typeface and style. To assure the visual sustainability, “Grindeks” proudly presents the novelty – Grindelia flower symbol, as one of the companies’ recognition signs, honouring the first Latvian origin pharmacist, doctor and chemist David Hireonymus Grindel.For more than 20 years company is known and trusted under the brand name “Grindeks”. Company’s name holds the history, traditions and evolution of all Latvian pharmaceutical industry. “Grindeks” launched novel brand vision to provide the best health support for every person worldwide and become a world-class pharmaceutical company.Growth, simplicity and humanity are the new “Grindeks” brand values, that will deliver experience and knowledge collected over the years in understandable and accessible manner.JSC “Grindeks” Chairman of the Council Kirovs Lipmans: “2021 is the year of “Grindeks” 75th anniversary and we will start it with inspirational changes. I have always believed that one should never stop on what has been accomplished and always reach towards the development. The new corporate values – humanity, simplicity and growth, as well as the visual brand innovations more than ever will bring out our main call – taking care of human health.”“Grindeks” brand changes will contribute to the implementation of the Group’s strategy by 2025, which includes increasing the range of the active pharmaceutical ingredients and the final dosage forms, expansion in new markets – European Union countries, US, Japan, South Korea, Australia and New Zealand; expansion of production infrastructure in Latvia, Estonia and Slovakia, as well as development of the subsidiary JSC “Kalceks”.Company also intends to change the medicine packaging design. Considering the complicated and time-consuming medicine registration process, transition to the new brand identity will be gradual.The video is available here: https://grindeks.eu/company/about-grindeks/The logo is available here: https://grindeks.eu/company/logo/
About JSC “Grindeks”“Grindeks” is an international pharmaceutical company focused on research, development, manufacturing and sales of original products, generics and active pharmaceutical ingredients. The Group of “Grindeks” has four subsidiary companies in Latvia, Estonia, and Slovakia as well as representative offices in 11 countries.“Grindeks” specializes in the heart and cardiovascular, CNS, anti-cancer and anti-diabetes medicines. A range of products covers a combination of original products Mildronate® (meldonium*) and Ftorafur®, generics and active pharmaceutical ingredients.In 2019, products of the company were exported to 84 countries. The most important export markets of “Grindeks” are the EU countries, Russia and other CIS countries, the USA, Canada and Japan. Further information:Laila KlavinaHead of the Communications Department, JSC “Grindeks”Phones: (+371) 67083370, (+371) 29256012Fax: (+371) 67083505laila.klavina@grindeks.lvwww.grindeks.eu

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.